Crosstalk of Immune Cells and Platelets in an Ovarian Cancer Microenvironment and Their Prognostic Significance

Pankowska, Katarzyna Aneta; Będkowska, Grażyna Ewa; Chociej-Stypułkowska, Joanna; Rusak, Małgorzata; Dąbrowska, Milena; Osada, Joanna

doi:10.3390/ijms24119279

Cited by 8 publications

(4 citation statements)

References 295 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A substantial information exchange occurs in the circulation between tumor cells, immune cells and circulating platelets (TEPs) ( 25 - 27 ). One study reported that PD-L1 mRNA expression in plasma-derived exosomes could help predict the clinical responses of melanoma or NSCLC patients who received anti-PD-1 therapy ( 28 ).…”

Section: Discussionmentioning

confidence: 99%

PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer

Hu,

Wang,

Zhang

et al. 2024

Transl Lung Cancer Res

View full text Add to dashboard Cite

Background To date, the role of programmed death ligand-1 (PD-L1) messenger RNA (mRNA) derived from tumor-educated platelets (TEPs) has not been well investigated in patients with advanced non-small cell lung cancer (NSCLC). A few reports have examined whether mRNA in TEPs can predict the clinical responses of patients with advanced NSCLC following immunotherapy. This study aimed to identify novel biomarkers to improve the clinical benefits and outcomes of NSCLC patients. Methods Advanced NSCLC patients receiving a combination of immunotherapy and chemotherapy, or immunotherapy alone as a first- or second-line treatment at the Fudan University Shanghai Cancer Center were enrolled in this study. All the patients had wild-type epidermal growth factor receptor/anaplastic lymphoma kinase. The patients were enrolled in clinical trials for immune checkpoint inhibitors (ICIs), including nivolumab, pembrolizumab, atezolizumab, durvalumab, tremelimumab, and camrelizumab. Tumoral PD-L1 expression was tested by immunohistochemistry (PD-L1 22C3 pharmDx kit, Agilent, Santa Clara, CA, USA) in archived tissue samples, when available, to calculate the tumor proportion scores (TPSs). RNA and exosomal RNA of blood were isolated before immunotherapy using the Yunying RNA extraction kit (Yunying Medicine, Shanghai, China). The concentration and quality of the RNA was determined using a Qubit fluorometer (Life Technologies, Carlsbad, CA, USA). Finally, we analyzed the predictive value of TEP-derived PD-L1 mRNA expression and association with the level of the tumoral PD-L1 expression. Results In total, 72 patients were enrolled in this study. Most of the patients were male (n=54, 75.0%), had adenocarcinoma (n=49, 68.1%). We found there was no significant correlation between the TEP-derived mRNA of PD-L1 and tumoral PD-L1 expression based on the results of the Pearson Correlation test (r=−0.19, P=0.233). Based on the median of PD-L1 mRNA, 72 patients were divided into a high PD-L1 group and a low PD-L1 group. We found that 19 patients (44.4%) responded to immunotherapy [partial response or progression-free survival (PFS) >6 months] in the high PD-L1 group, but only five patients (13.9%) responded to immunotherapy in the low PD-L1 group (P<0.01). The median PFS of the low PD-L1 group was lower than that of the high PD-L1 group (2.8 vs. 8.3 months, P<0.001). For the patients who were treated with immunotherapy alone (n=64), a similar PFS advantage was observed in the high PD-L1 group (2.8 vs. 8.0 months, P=0.002). Conclusions This article presented the first data on TEP-derived PD-L1 mRNA in advanced NSCLC patients following immunotherapy and showed the potential advantage of using it as the surrogate biomarker for predicting the PFS and overall survival of patients following immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer

Hu,

Wang,

Zhang

et al. 2024

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…18 Platelets are involved in immune evasion by interactions with tumor cells or through the secretion of a variety of growth factors and cytokines to promote tumor growth and angiogenesis. 19 The serum albumin level is an indicator of nutritional status. Hypoalbuminemia may occur as a systemic inflammatory response and reflects malnutrition or cachexia because of tumor progression.…”

Section: Discussionmentioning

confidence: 99%

Impact of albumin–lymphocyte–platelet–C‐reactive protein index as a prognostic indicator of hepatocellular carcinoma after resection: Associated with nuclear factor erythroid 2–related factor 2

Iseda,

Itoh,

Toshida

et al. 2023

Hepatology Research

View full text Add to dashboard Cite

AimTo investigate the prognostic value of preoperative albumin‐lymphocyte‐platelet‐c‐reactive protein (ALPC) index in patients with hepatocellular carcinoma (HCC) undergoing curative hepatectomy. We also evaluated with the relationship of the ALPC index and phosphorylated nuclear factor erythroid 2‐related factor 2 (p‐Nrf2) levels.MethodsData were analyzed retrospectively from 256 patients who underwent resection for HCC. For cross‐validation, patients were divided into the training and testing cohort. We assessed eight combinations of inflammatory markers for predictive value for recurrence. We examined the associations of the ALPC index with recurrence‐free survival (RFS) and overall survival (OS) in univariate and multivariate analyses (Cox proportional hazards model). Immunohistochemical staining of p‐Nrf2 was performed on tumor samples of 317 patients who underwent hepatic resection for HCC.ResultsHigh preoperative ALPC index correlated with a high serum albumin concentration, small tumor size, a low rate of poor differentiation, solitary tumor, early Barcelona Clinic Liver Cancer stage and a low rate of microscopic intrahepatic metastasis in the training dataset. High preoperative ALPC index correlated with a high serum albumin concentration, high serum alpha‐fetoprotein concentration, small tumor size, a low rate of poor differentiation and a low rate of microscopic intrahepatic metastasis in the testing dataset. Higher preoperative ALPC index was an independent predictor of longer RFS and OS in the training and testing datasets. High ALPC index was associated with negative p‐Nrf2 expression in HCC tumor cells.ConclusionsWe showed that a high ALPC index was an independent prognostic factor for HCC patients undergoing curative hepatic resection.This article is protected by copyright. All rights reserved.

show abstract

“…Research has highlighted the prognostic value of TAMs in OC, particularly through the assessment of ratios like M1/M2 and M2/TAMs. However, the overall density of TAMs in ovarian tumors has not demonstrated significant prognostic significance [6,8,27,[41][42][43].…”

Section: Role Of Tumor Microenvironment In Ovarian Cancer Progressionmentioning

confidence: 99%

“…TGFβ plays a key role in polarizing TANs, suppressing N1, and promoting N2 phenotypes. However, the functional plasticity of TANs in human OC is not well studied [6,42,46,47].…”

Section: Role Of Tumor Microenvironment In Ovarian Cancer Progressionmentioning

confidence: 99%

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

Szymanowski,

Szymanowska,

Bielawska

et al. 2023

Cancers

View full text Add to dashboard Cite

Ovarian cancer (OC) is the most common lethal gynecologic cause of death in women worldwide, with a high mortality rate and increasing incidence. Despite advancements in the treatment, most OC patients still die from their disease due to late-stage diagnosis, the lack of effective diagnostic methods, and relapses. Aptamers, synthetic, short single-stranded oligonucleotides, have emerged as promising anticancer therapeutics. Their ability to selectively bind to target molecules, including cancer-related proteins and receptors, has revolutionized drug discovery and biomarker identification. Aptamers offer unique insights into the molecular pathways involved in cancer development and progression. Moreover, they show immense potential as drug delivery systems, enabling targeted delivery of therapeutic agents to cancer cells while minimizing off-target effects and reducing systemic toxicity. In the context of OC, the integration of aptamers with non-coding RNAs (ncRNAs) presents an opportunity for precise and efficient gene targeting. Additionally, the conjugation of aptamers with nanoparticles allows for accurate and targeted delivery of ncRNAs to specific cells, tissues, or organs. In this review, we will summarize the potential use and challenges associated with the use of aptamers alone or aptamer–ncRNA conjugates, nanoparticles, and multivalent aptamer-based therapeutics for the treatment of OC.

show abstract

Crosstalk of Immune Cells and Platelets in an Ovarian Cancer Microenvironment and Their Prognostic Significance

Cited by 8 publications

References 295 publications

PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer

PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer

Impact of albumin–lymphocyte–platelet–C‐reactive protein index as a prognostic indicator of hepatocellular carcinoma after resection: Associated with nuclear factor erythroid 2–related factor 2

Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges

Contact Info

Product

Resources

About